

Kidney Suite Guideline Update - Committee Meeting

Date: 09/09/20

Location: Virtual

Minutes: Final

Committee members present:	
Anthony Wierzbicki (AW)	Present for notes 1 – 9
Virginia Aylett (VA)	Present for notes 1 – 9
Clare Allinson (CA)	Present for notes 1 – 8
Tara Bashford (TB)	Present for notes 1 – 9
Neel Basudev (NB)	Present for notes 4 – 9
Ivan Benett (IB)	Present for notes 3 – 9
Roy Connell (RC)	Present for notes 1 – 5
Grainne Connolly (GC)	Present for notes 1 – 9
Jan Dudley (JD)	Present for notes 1 – 9
Hugh Gallagher (HG)	Present for notes 1 – 9
Deepa Kariyawasam (DK)	Present for notes 1 – 9
Arif Khwaja (AK)	Present for notes 2 – 9
Andrew Lewington (AL)	Present for notes 2 – 9
Fiona Loud (FL)	Present for notes 1 – 5
Rajib Pal (RP)	Present for notes 1 – 9
Catherine Pogson (CP)	Present for notes 1 – 9
Nicola Thomas (NT)	Present for notes 1 – 9

In attendance:		
Omnia Abdulrazeg (OA)	Technical Analyst	Present for notes 1 – 9
Steph Armstrong (SA)	Technical Analyst	Present for notes 1 – 9

Kidney Suite GComm 11 minutes

	Health Economics	
Victoria Axe (VA)	Commissioning Manager	Present for notes 1 – 9
Lucy Beggs (LB)	Technical Adviser – Health Economics	Present for notes 1 – 3
Chris Carmona (CC)	Senior Technical Analyst	Present for notes 1 – 9
Jackie Durkin (JD)	Administrator	Present for notes 1
Yolanda Martinez (YM)	Technical Analyst	Present for notes 1 – 9
Vonda Murray (VM)	Project Manager	Present for notes 1 – 9
Joshua Pink (JP)	Technical Adviser – Health Economics	Present for notes 1 – 3

Apologies:

Sarah Ali	Co-opted Committee Member
Clare Allinson	Committee member
Caroline Keir	NICE – Commissioning Manager
Susan Spiers	Associate Director

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the 11th committee meeting on Kidney Injury & Disease. The Chair welcomed to the meeting; committee members, and NICE attendees.

The Chair introduced VM Project Manager, who provided a recap on zoom functions. The Chair thanked VM for her presentation.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Review and discussion of the health economics model
- Review of recommendations for adults, children and young people with CKD, what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality.
- Review of recommendations for adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria
- Review and discussion of the evidence for adults, children and young people

Kidney Suite GComm 11 minutes

with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression

- Review and discussion of the evidence for adults, children and young people with CKD, what is the optimal monitoring frequency based on different rates of decline in eGFR?

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, and any new interests did not prevent the attendees from fully participating in the meeting. New interests are noted below:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Neel Basudev	GP, Springfield Medical Centre, London	Chairing and speaker's fee. Merck & Co. Pharmaceutical Company Non-promotional evening talk to local GPs and Practice nurses on Type 2 Diabetes management	Direct, financial	Declare and participate
Neel Basudev	GP, Springfield Medical Centre, London	Speaker's fee Sanofi Aventis Pharmaceutical company Non-promotional	Direct, financial	Declare and participate
Neel Basudev	GP, Springfield Medical Centre, London	Flights, conference and hotel registration from Sanofi. Attendance to EASD (European Association for the Study of Diabetes) in Barcelona. No Honorarium	Direct, financial	Declare and participate
Neel Basudev	GP, Springfield Medical Centre, London	Fee for Chairing the Medicines Optimisation meeting at King's Fund for pharmacists. Non promotional event for pharmacy optimisation case studies and shared	Direct, financial	Declare and participate

Kidney Suite GComm 11 minutes

		learning sponsored by Takeda Pharmaceutical company		
Neel Basudev	GP, Springfield Medical Centre, London	Diabetes Lead, Lambeth CCG	Direct, non-financial professional and personal	Declare and participate
Neel Basudev	GP, Springfield Medical Centre, London	Clinical Director Diabetes, Health Innovation Network, South London Academic Health Science Network	Direct, non-financial professional and personal	Declare and participate
Neel Basudev	GP, Springfield Medical Centre, London	Clinical Lead Out of Hospital Care, London Diabetes Clinical Network	Direct, non-financial professional and personal	Declare and participate
Neel Basudev	GP, Springfield Medical Centre, London	Committee member on the NICE diabetes update committee	Direct, non-financial professional and personal	Declare and participate
Nicola Thomas	Professor of Kidney Care, School of health and Social care, London South Bank University	Lead investigator for study to evaluate the feasibility of using smartphone technology for home urine testing in people with diabetes and/or chronic kidney disease in East London for Burdett Trust	Indirect financial	Declare and participate
Nicola Thomas	Professor of Kidney Care, School of health and Social care, London South Bank University	Appointed to Diaverum Medical Advisory Board, a provider of renal care services	Direct financial	Declare and participate

The Chair asked the Committee if it wanted any changes made to the minutes of GComm 9 and GComm10. A missing word (Chair) was identified in the minutes of GComm 9, page 2 item agenda 1. The Committee agreed that the minutes were a true and accurate account of the meeting, subject to the change noted above.

Kidney Suite GComm 11 minutes

Action – VM, update GComm 9 minutes

2. Health Economics modelling

The Chair introduced SA, Technical Analyst – Health Economics and JP Technical Adviser – Health Economics, who gave a presentation on the health economic model. The Chair thanked SA & JP for their presentation.

3. RQ4.1 In adults, children and young people with CKD, what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality?

- Recommendation review

The Chair introduced OA, Technical Analyst, who led a discussion around the review question on adults, children and young people with CKD, what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality. The Chair thanked OA for leading the discussion.

4. RQ2.3 For adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria?

- Recommendation review

The Chair introduced YM, Technical Analyst, who led a discussion around the review question on for adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria. The Chair thanked YM for leading the discussion.

5. RQ3.1 For adults, children and young people with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease

Kidney Suite GComm 11 minutes

progression? <ul style="list-style-type: none">• Evidence presentation
The Chair introduced YM, Technical Analyst, who gave a presentation on adults, children and young people with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression. The Chair thanked YM for her presentation.
6. RQ3.2 For adults, children and young people with CKD, what is the optimal monitoring frequency based on different rates of decline in eGFR? <ul style="list-style-type: none">• Evidence presentation
The Chair introduced OA, Technical Analyst, who gave a presentation on adults, children and young people with CKD, what is the optimal monitoring frequency based on different rates of decline in eGFR. The Chair thanked OA for her presentation.
7. RQ3.1 For adults, children and young people with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression? RQ3.2 For adults, children and young people with CKD what is the optimal monitoring frequency based on different rates of decline in eGFR? <ul style="list-style-type: none">• Recommendation discussion
The Chair facilitated a discussion around the review questions on adults, children and young people with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression and what is the optimal monitoring frequency based on different rates of decline in eGFR.
8. AOB
None
9. Summary and next steps
The Chair thanked the committee for their time and contribution to the meeting and reminded the committee of the date and time of the next committee meeting

Date of next meeting: 21/09/20 – 13:45 to 16:30

Location of next meeting: Virtual